三生制药创新管线兑现,迎出海新篇章

中信建投
Aug 04

PD-1/VEGF双抗成功授权,创新能力得到验证。公司SSGJ-707基于CLF2平台开发,临床推进迅速,已在国内开展四项I/1期研究,覆盖NSCLC、CRC和妇科肿瘤,其中NSCLC一线Ⅲ期试验正对标Keytruda,海外亦启动FDA I期临床。II期数据显示,其在多瘤种中显示优效与良好安全性。2025年5月,公司与辉瑞达成总额60.5亿美元授权合作,并获1亿美元投资,显示全球巨头对其创新力和...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10